Acorn Financial Advisory Services Inc. ADV grew its stake in Johnson & Johnson (NYSE:JNJ) by 27.8% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 6,857 shares of the company’s stock after purchasing an additional 1,492 shares during the period. Acorn Financial Advisory Services Inc. ADV’s holdings in Johnson & Johnson were worth $964,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Old North State Trust LLC increased its stake in shares of Johnson & Johnson by 0.5% in the 2nd quarter. Old North State Trust LLC now owns 13,666 shares of the company’s stock valued at $1,922,000 after purchasing an additional 71 shares in the last quarter. Hexavest Inc. increased its stake in shares of Johnson & Johnson by 6.6% in the 2nd quarter. Hexavest Inc. now owns 1,186,815 shares of the company’s stock valued at $166,902,000 after purchasing an additional 73,962 shares in the last quarter. Forte Capital LLC ADV increased its stake in shares of Johnson & Johnson by 6.7% in the 2nd quarter. Forte Capital LLC ADV now owns 19,192 shares of the company’s stock valued at $2,685,000 after purchasing an additional 1,202 shares in the last quarter. LGT Capital Partners LTD. increased its stake in shares of Johnson & Johnson by 16.8% in the 2nd quarter. LGT Capital Partners LTD. now owns 106,630 shares of the company’s stock valued at $14,995,000 after purchasing an additional 15,300 shares in the last quarter. Finally, Aries Wealth Management increased its stake in shares of Johnson & Johnson by 1.5% in the 2nd quarter. Aries Wealth Management now owns 28,439 shares of the company’s stock valued at $3,999,000 after purchasing an additional 422 shares in the last quarter. 68.51% of the stock is owned by institutional investors and hedge funds.

NYSE:JNJ traded down $0.39 during trading hours on Friday, reaching $142.10. 1,675,318 shares of the stock were exchanged, compared to its average volume of 7,051,240. The company has a quick ratio of 1.05, a current ratio of 1.31 and a debt-to-equity ratio of 0.41. The business has a 50-day moving average of $143.84 and a two-hundred day moving average of $143.95. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The company has a market capitalization of $377.46 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 3.12 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.27. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The company had revenue of $20.69 billion for the quarter, compared to analysts’ expectations of $19.48 billion. During the same period in the prior year, the firm earned $2.10 earnings per share. The firm’s revenue was up 3.3% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 7.7 EPS for the current fiscal year.

JNJ has been the subject of several recent analyst reports. Citigroup lifted their price target on Johnson & Johnson from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, April 15th. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target for the company. in a research report on Tuesday. Morgan Stanley upped their price objective on Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Wells Fargo & Co upgraded Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Finally, Argus reiterated a “buy” rating and issued a $155.00 price objective (down from $165.00) on shares of Johnson & Johnson in a report on Friday, March 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have issued a buy rating to the company. Johnson & Johnson presently has an average rating of “Buy” and an average target price of $162.93.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: What is a Special Dividend?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.